Given the genetic and biologic similarities of NHL in dogs and people, clinical responses to PI3K inhibitor treatment in dogs with NHL are expected to accurately predict responses and toxicities in humans. The gene discussed is PIK3CA; the disease is non-Hodgkin lymphoma.